Cancer ke baare mein jab hum numbers sunte hain—

survival rate, percentage, statistics—

toh aksar darr badh jaata hai.

Is episode mein OncoPODindia par hum simple Hindi/Hinglish mein samjhaate hain:

• ​ 5-year survival ka matlab kya hota hai
• ​ Yeh numbers aapke future ko decide kyun nahi karte
• ​ Kaise cancer survival aaj pehle se kaafi better ho chuki hai

Aaj science ke data ke hisaab se:

• ​ Har 10 mein se lagbhag 7 cancer patients 5 saal ya usse zyada jee rahe hain
• ​ Advanced cancers jaise lung cancer, rectal cancer, melanoma, aur blood cancers mein survival rates 1990s ke mukable double ho chuke hain

Yeh episode numbers se darr paida karne ke liye nahi—

numbers ko sahi context mein samajhne ke liye hai.

🎙️ Hosted by Dr. Faraz Badar, Radiation Oncologist

📊 Data based on large international cancer studies, including the American Cancer Society

Message simple hai:

Cancer aaj pehle jaisa nahi raha—

aur aaj ki umeed science par based hai.

Cancer Awareness, Cancer Survival, Cancer Statistics, 5 Year Survival, Oncology, Hindi Health Podcast, Cancer Education, Indian Cancer Podcast, OncoPODindia, Cancer Hope, Radiation Oncology, Health Awareness India

Cancer is no longer the diagnosis it once was.

In this short episode of OncoPODindia, we share encouraging, science-backed insights showing how modern medicine has transformed cancer care. Today, nearly 70% of people diagnosed with cancer are alive five years later, and survival has improved dramatically—even for advanced-stage cancers.

From targeted therapies to immunotherapy and precision medicine, science is helping patients live longer and better lives.

This episode is for patients, families, and anyone who believes that early diagnosis, timely treatment, and trust in science can change outcomes.

🎙️ Hosted by Dr. Faraz Badar, Radiation Oncologist

📌 OncoPODindia – bringing clarity, compassion, and credible cancer information

Molecular classification of medulloblastoma is now firmly in place. In this episode the 4 key subtypes that is

1. WNT ACTIVATED
2. SHH ACTIVATED (p53 mutant and wild type)
3. GROUP 3
4. GROUP 4

are discussed with an emphasis on how these differ from each other. Also you will get to know what additional information this molecular classification will give to clinicians. If you are more of an instagrammer you may like to visit the instagram page where this topic has been presented in text format.

Here is the link to instagram profile: https://www.instagram.com/oncopodindia/

please share your feedback on oncopodindia@gmail.com

Endometrial cancer is the most common gynaecological cancer in developed countries. In this episode of OncoPODindia, the traditional dualistic classification (Type I vs Type II endometrial cancer) is discussed. Although the cancer genome atlas has come up with new molecular classification of endometrial cancer, still the older traditional classification remains very important. This comparative analysis is a part of PROJECT VERSUS where complex topics are presented in a comparative manner so as to make them easy to understand.

Feedbacks are welcome and eagerly awaited.

Please follow us on instagram ( OncoPODindia ) where these differences have been put in infographics format.

You can also mail us on oncopodindia@gmail.com

Comparison between two very important class of chemotherapy drugs i.e. Vinka Alkaloids and taxanes.

In this episode, key differences between childhood and adult medulloblastoma is enumerated